From: Future possibilities in the prevention of breast cancer: Breast cancer prevention trials
 |  |  |  |  | Compliance (%) |  | |
---|---|---|---|---|---|---|---|
Trial | Age (median; years) | Age <50 years (%) | First-degree relative with breast cancer (%) | Two or more relatives with breast cancer (%) | Tamoxifen/raloxifene | Placebo | HRT use on study (%) |
RMH [5*] | 47 | 62 | 96 | 42 | 74 | 86 | 26 |
NSABP [3*] | 50-59 | 37 | 76 | 33 | 76 | 80 | <10 |
Italian [6*] | 51 | 38 | 12 | ? | 80 | 75 | 12 |
IBIS* | 50 | 51 | 91 | 30 | 74 at 4 years | Â | 22 |
MORE [7*] | 67 | Very few | 12†| ? | 78 at 3 years | 75 | 10‡ |